

[54] **PHARMACEUTICAL COMPOSITION CONTAINING 1-(MONO- OR BIS(TRIFLUOROMETHYL)-2-PYRIDINYL)-PIPERAZINES**

[75] **Inventors:** **Patrick Carlier; André Monteil**, both of Chatel-Guyon; **Claude Poisson**, Riom, all of France

[73] **Assignee:** **Akzo N.V.**, Arnhem, Netherlands

[21] **Appl. No.:** **439,964**

[22] **Filed:** **Nov. 21, 1989**

[30] **Foreign Application Priority Data**

Nov. 24, 1988 [EP] European Pat. Off. 88.402965.3

[51] **Int. Cl.⁵** **A61K 31/495; C07D 401/04**

[52] **U.S. Cl.** **514/252; 544/360**

[58] **Field of Search** **544/360; 514/252**

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,876,256 10/1989 Coss et al. 544/360

FOREIGN PATENT DOCUMENTS

177392 4/1986 European Pat. Off. 544/360

OTHER PUBLICATIONS

Saari et al., *J. Med. Chem.* 1983, 26, 1696-1701.

Abou-Gharbia, *Chem. Abst.* 107-217647d, eq. EP 220873 cited in the specification.

Lavielle et al., *Chem. Abst* 110-75296z (1989) eq. EP 282390 cited in the specification.


Primary Examiner—Cecilia Shen

Attorney, Agent, or Firm—William M. Blackstone

[57]

ABSTRACT

Pharmaceutical composition which is useful as a medicinal product, in particular for the treatment of disorders of the central nervous system, characterized in that it contains customary pharmaceutical excipients, and at least one of the compounds of formula



in which the trifluoromethyl substituent is at the 4-position, at the 5-position, or at 4- and 5-positions of the pyridinyl ring, and the substituent R denotes either hydrogen or a halogen, such as chlorine, at position(s) of the pyridinyl ring not occupied by CF₃, and its pharmaceutically acceptable salts.

6 Claims, No Drawings